Charts

The high-flyers have soared to new heights and further gains could be up ahead.

Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had entered an unusual global deal with Seagen.

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around150 points on Monday. The Dow ...

Gainers Provention Bio (NASDAQ:PRVB) stock moved upwards by 260.1% to $24.12 during Monday's regular session. As of 13:30 EST, ...

Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for ...

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 300 points on Monday. The Dow traded up 0.94% to ...

Calliditas Therapeutics AB(NASDAQ: CALT) announcedtopline resultsfrom the Phase 3 clinical trial NefIgArd, which ...

U.S. stocks traded slightly lower, with the Nasdaq Composite dropping around 0.2% on Monday. Here are some big stocks recording gains in ...

U.S. stocks traded mostly higher this morning, with the Dow Jones gaining around 75 points on Monday. Following the market opening ...

Gainers Provention Bio (NASDAQ:PRVB) stock increased by 260.7% to $24.17 during Monday's pre-market session. The market value of their ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon (TARPEYO®/Kinpeygo® (budesonide) delayed release capsules) versus placebo in patients with primary IgA nephropathy (IgAN).

Guggenheiminitiated coverage onCalliditas Therapeutics AB(NASDAQ: CALT) with a Neutral rating andan $18 price ...

Upgrades According to UBS, the prior rating for Procter & Gamble Co (NYSE:PG) was changed from Neutral to Buy. In the second ...

U.S. stocks traded slightly lower, with the Dow Jones dropping around 30 points on Thursday. Here are some big stocks recording gains in ...

Gainers TransMedics Group (NASDAQ:TMDX) stock moved upwards by 16.4% to $75.1 during Thursday's pre-market session. The market value of ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the day with a look at all the biggest pre-market stock movers traders need to know about on Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

"2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for IgA nephropathy and a medication with the potential to be disease modifying based on the early stabilization of eGFR in patients at risk of rapid disease progression. We achieved total revenues of SEK 802.9 million ($79.3m) for the year of 2022, which represent an increase of 250% compared to 2021, whereof SEK 372.2 million ($36.8m) was net sales of TARPEYO for the first 11 months of commerci

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has granted Conditional Marketing Authorization (CMA) for Kinpeygo® for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram.

During January, Calliditas Therapeutics AB (publ) has issued 7,500 common shares connected to the company's long term incentive program 2019/2022. Thus, as of January 31, 2023, the number of shares and votes in the company amounts to 59,580,087 shares and 59,580,087 votes.

CALT, CVGW and DFH have been added to the Zacks Rank #5 (Strong Sell) List on January 6, 2023.

Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has recommended Priority Review for the New Drug Application (NDA) of Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of rapid disease progression.

Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced today that CEO Renée Aguiar-Lucander has net purchased 50,000 shares through Calliditas' warrant program 2019/2022. Following the new subscription for shares, her shareholding in the company will amount to 643,000 common shares.

Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") announced today that they have entered into an exclusive license agreement with Viatris Pharmaceuticals Japan Inc., a subsidiary of Viatris Inc. (NASDAQ: VTRS) ("Viatris"), to register and commercialize Nefecon, a specialty drug recently approved in Europe and the US for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN) in Japan.

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a fireside chat with its commercial partner Everest Medicines (HKEX 1952.HK, "Everest") on Wednesday, December 14th, 2022 at 8am Eastern Time (2pm Central European Time, 8pm China Standard Time).

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Chinese regulatory authority National Medical Products Administration ("NMPA") has accepted Everest Medicines' (HKEX 1952.HK, "Everest") New Drug Application ("NDA") for Nefecon. The acceptance brings Nefecon, approved and marketed in the U.S. under the name TARPEYO® and in the E.U. as Kinpeygo®, an important step closer to potentially becoming the first-ever approved therapeutic option in

"On July 15th the European Commission issued the conditional marketing authorization for Kinpeygo, which marked the first time that any drug has achieved approval for this rare disease in EU. We immediately started the process of transferring the market authorization to our European partner, STADA Arzneimittel AG, in order to enable a launch in Europe as quickly as possible. STADA is initially launching the product in Germany, with other European countries to follow over time.

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a Key Opinion Leader (KOL) Fireside Chat on the IgA Nephropathy (IgAN) treatment landscape in the US on Tuesday, November 8th, 2022 at 1:30pm Eastern Time.

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday. Altamira Therapeutics Ltd. ...

Gainers Altamira Therapeutics Ltd. (NASDAQ: CYTO) surged 67% to $0.5484 after the company announced divestiture of its inner ear ...

Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 40.9% to $0.2160 in pre-market trading. Statera Biopharma recently signed a ...

U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading ...

Gainers NextPlay Technologies, Inc. (NASDAQ: NXTP) shares climbed 107.3% to close at $0.4138 on Thursday after the company ...

The nomination committee, which is appointed in accordance with the principles adopted by the extraordinary general meeting in 2017, consists of:

Gainers Cabaletta Bio (NASDAQ:CABA) shares rose 37.8% to $1.79 during Thursday's regular session. As of 13:30 EST, Cabaletta ...

Gainers NextPlay Technologies, Inc. (NASDAQ: NXTP) shares jumped 126% to $0.4525 after the company announced its NextFintech ...

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced Kidney International has published the successful results from NefIgArd Part A, their pivotal Phase 3, randomized, double-blind, placebo-controlled, multicenter study.

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that its European commercial partner, STADA Arzneimittel AG, has launched the first and only approved treatment in the EU for primary immunoglobulin A nephropathy (IgAN), a rare, progressive disease of the kidneys with a high unmet need. STADA will initially launch in Germany with additional European countries to follow.

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday. Plus Therapeutics, ...

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66. Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) ...

Bed Bath & Beyond Inc. (NASDAQ: BBBY) fell 23.3% to $17.71 following a Form 144 filing by RC Ventures, which suggested the ...

Calliditas Therapeutics (NASDAQ:CALT) reported its Q2 earnings results on Thursday, August 18, 2022 at 01:00 AM. Here's ...

Companies Reporting Before The Bell • Calliditas Therapeutics (NASDAQ:CALT) is expected to report quarterly loss at ...

European approval for Kinpeygo®

Calliditas Therapeutics (NASDAQ:CALT) is set to give its latest quarterly earnings report on Thursday, 2022-08-18. Here's ...

In trading on Monday, shares of Calliditas Therapeutics AB (CALT) crossed above their 200 day moving average of $18.98, changing hands as high as $20.26 per share. Calliditas Therapeutics AB shares are currently trading up about 6.7% on the day..

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Sesen Bio To Pause Clinical ...

The European Commission (EC) has granted conditional marketing authorization for Calliditas Therapeutics’s (NASDAQ: CALT) Kinpeygo ...

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 ...

Gainers Revlon, Inc. (NYSE: REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying ...

Gainers Mereo BioPharma Group (NASDAQ:MREO) shares increased by 41.2% to $1.13 during Friday's pre-market session. ...

Gainers Athersys, Inc. (NASDAQ: ATHX) rose 48.5% to $0.4755 in pre-market trading after dropping more than 12% on ...

Gainers Clovis Oncology (NASDAQ:CLVS) stock increased by 32.8% to $0.93 during Tuesday's pre-market session. The ...

In trading on Wednesday, shares of Calliditas Therapeutics AB - American Depositary S (CALT) crossed above their 200 day moving average of $20.12, changing hands as high as $20.54 per share. Calliditas Therapeutics AB - American Depositary S shares are currently trading up about 4.1% on the day..

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) hasadopted a positive ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus FDA Gives Green Signal To ...

Gainers Kiromic BioPharma (NASDAQ:KRBP) shares moved upwards by 17.3% to $0.4 during Wednesday's pre-market session. ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're getting ready for another full day of trading with a breakdown of the biggest pre-market stock movers for Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Gainers Decisionpoint Systems, Inc. (NASDAQ: DPSI) rose 47.2% to $7.02 in pre-market trading after jumping around 19% on Tuesday. ...

Companies Reporting Before The Bell • Sypris Solutions (NASDAQ:SYPR) is projected to report earnings for its first ...

Calliditas Therapeutics (NASDAQ:CALT) is set to give its latest quarterly earnings report on Wednesday, 2022-05-18. Here's what ...